Cost consequences of HIV-associated lipoatrophy

Author： Hornberger J.   Rajagopalan R.   Shewade A.   Loutfy M. R.  

Publisher： Routledge Ltd

ISSN： 1360-0451

Source： AIDS Care, Vol.21, Iss.5, 2009-05, pp. : 664-671

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

An Economic Evaluation of Treatments for HIV-Associated Facial Lipoatrophy: A Cost-Utility Analysis

By  

Current HIV Research, Vol. 8, Iss. 5, 2010-07 ,pp. : 386-395

Bentham Science Publishers

Access to resources Recommend Favorite

Long-term efficacy and safety of polyalkylimide gel for the treatment of HIV-associated lipoatrophy

By Antoniou Tony   Raboud Janet   Kovacs Colin   Diong Christina   Brunetta Jason   Smith Graham   Halpenny Roberta   Beninger Francis   Loutfy Mona  

AIDS Care, Vol. 21, Iss. 10, 2009-10 ,pp. : 1247-1252

Routledge Ltd

Access to resources Recommend Favorite

Diagnosis and treatment of HIV-associated nephropathy

By Betjes M.G.H.   Weening J.   Krediet R.T.  

The Netherlands Journal of Medicine, Vol. 59, Iss. 3, 2001-09 ,pp. : 111-117

Elsevier

Access to resources Recommend Favorite

HIV-Associated Multiple Intracerebral Hemorrhages

By  

European Neurology, Vol. 53, Iss. 2, 2005-05 ,pp. : 100-102

Karger

Access to resources Recommend Favorite

Rituximab therapy for HIV-associated multicentric Castleman disease

By Veraitch Ophelia   Bower Mark   Shackleton David   Stebbing Justin  

HIV Therapy, Vol. 4, Iss. 3, 2010-05 ,pp. : 281-284

Future Medicine

Access to resources Recommend Favorite